Schizophrenia Clinical Trial
Official title:
A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Verified date | February 2017 |
Source | Otsuka Pharmaceutical Development & Commercialization, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Male and female subjects 13 to 17 years of age, inclusive, at the time of informed consent. - Subjects with a current diagnosis of primary schizophrenia spectrum or bipolar spectrum disorder, as defined by DSM-IV-TR criteria, and confirmed by K-SADS-PL. - No psychiatric hospitalizations within the past 12 weeks. - Subjects require treatment with antipsychotic medications. - Subjects who have received previous outpatient antipsychotic treatment at an adequate dose for an adequate duration (at least 6 weeks) and who showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months. - Subjects with a body weight at Screening greater than or equal to 30 kg. Exclusion Criteria: - Sexually active females of childbearing potential and male subjects who are not practicing two different methods of birth control with their partner (or abstinence) during the trial and for 30 days after the last dose of trial medication - Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving trial drug. - Subjects who have received continuous medication therapy to treat schizophrenia and schizophrenia spectrum diagnosis for less than six months prior to first dose of study medication AND subjects who have received continuous medication therapy to treat bipolar and bipolar spectrum disorder for less than two months in the past three years; or subjects who require more than one antipsychotic.. - Subjects with a current DSM-IV-TR diagnosis other than schizophrenia spectrum , bipolar spectrum, including any Axis I or Axis II (DSM-IV-TR) disorder. - Subjects with a clinical presentation and/or history of any neurodevelopmental disorder - Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days. - Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV seropositive status/acquired immunodeficiency syndrome, or chronic hepatitis B or C. - Subjects with IDDM (ie, any subjects using insulin) are excluded. Subjects with non-IDDM may be eligible for the trial if their condition is stable. - Subjects with epilepsy or a history of seizures. - Any major surgery or blood transfusion within 30 days prior to first dose of trial medication. - Subjects with a positive drug screen for cocaine or other illicit drugs, or alcohol are excluded and may not be retested or re-screened. - Prohibited concomitant medications used within the exclusionary period prior to Day 1 of the Dose Escalation Phase or anticipated need for such medications during the trial. - Subjects who participated in a clinical trial and were exposed to IMP within the last 30 days or who participated in more than two interventional clinical trials within the past year. - Subjects with a history of true allergic response (ie, not intolerance) to more than one class of medications. - Inability to tolerate oral medication or swallow tablets. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc. | H. Lundbeck A/S |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reported Adverse Events (AEs) at 30 day Follow-Up | 30 day Follow-Up | ||
Primary | Change from Baseline to Day 17 in Vital Signs | Baseline to Day 17 | ||
Primary | Change from Baseline to Day 17 ECGs | Baseline to Day 17 | ||
Primary | Change from Baseline to Day 17 Hematology | Baseline to Day 17 | ||
Primary | Change from Baseline to Day 14 Physical examination | Baseline to Day 14 | ||
Primary | Change from Baseline to Day 17 Body weight | Baseline to Day 17 | ||
Primary | Change from Baseline to Day 17 Serum chemistry | Including Prolactin concentrations | Baseline to Day 17 | |
Primary | Change from Baseline to Day 17 Urinalysis | Baseline to Day 17 | ||
Primary | Maximal peak steady-state plasma concentration | At Day 14 | ||
Primary | Minimum trough steady-state plasma concentration | At Day 14 | ||
Primary | Time to maximum peak steady-state plasma concentration | At Day 14 | ||
Primary | Area under the concentration-time curve during the dosing interval at steady-state | At Day 14 | ||
Primary | Terminal elimination half-life | At Day 14 | ||
Primary | For Brex only, apparent cleanse and apparent volume of distribution | At Day 14 | ||
Secondary | Mean change in CGI-S score | Day -1 of Dose Titration Phase to Day 7 and Day 14 of Fixed Dose Phase | ||
Secondary | Mean change in CGI-I score | Day 7 and Day 14 | ||
Secondary | Glycosylated haemoglobin [HbA1c] | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 Adrenocorticotropic hormone [ACTH] | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 Cortisol | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 Thyroid stimulating hormone [TSH] | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 Prothrombin time [PT] | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 Activated partial thromboplastin time [aPTT] | Baseline to Day 17 | ||
Secondary | Change from Baseline to Day 17 International normalized ratio [INR] | Baseline to Day 17 | ||
Secondary | For subjects with a current primary schizophrenia spectrum diagnosis, mean change in Positive and Negative Syndrom Scale (PANSS) | Day-1 to Day 15 | ||
Secondary | For subjects with a current diagnosis of bipolar spectrum disorder, mean change in Young Mania Rating Scale (YMRS) | Day -1 to Day 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |